10-KPeriod: FY2010

ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2010

Filed February 18, 2011For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2010 annual report, highlighting its strategic focus on RNA interference (RNAi) therapeutics. The company is advancing its 'Alnylam 5x15' strategy, aiming to bring five RNAi therapeutic programs into advanced clinical development by the end of 2015. Alnylam is currently developing three core programs: ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. Financially, Alnylam reported net revenues from research collaborators of $100.0 million for 2010, with total operating expenses of $144.1 million, resulting in a net loss of $43.5 million. The company ended 2010 with $349.9 million in cash, cash equivalents, and marketable securities, indicating a strong cash position to fund ongoing research and development activities. Alnylam also emphasized its robust intellectual property portfolio and a strong base of strategic alliances with major pharmaceutical companies, which provide significant financial support and operational capabilities.

Financial Highlights

43 data points
Beta

Revenue

$100.04M

Net Income

-$43.52M

-43.5% Net Margin

EPS (Diluted)

$-1.04

Total Assets

$393.26M

Cash & Equivalents

$74.60M

Free Cash Flow

-$89.07M

Financial Statements
Beta
Revenue$100.04M
R&D Expenses$106.38M
Operating Expenses$144.11M
Operating Income-$44.07M
Net Income-$43.52M
EPS (Basic)$-1.04
Shares Outstanding (Basic)42.04M

Key Highlights

  • 1Alnylam is advancing its 'Alnylam 5x15' strategy, targeting five RNAi therapeutic programs for advanced clinical development by 2015.
  • 2Key development programs include ALN-TTR (ATTR), ALN-PCS (severe hypercholesterolemia), and ALN-HPN (refractory anemia).
  • 3Net revenues from research collaborators reached $100.0 million in 2010.
  • 4The company reported a net loss of $43.5 million for 2010.
  • 5Alnylam maintained a strong cash position with $349.9 million in cash, cash equivalents, and marketable securities at year-end 2010.
  • 6A significant corporate restructuring in September 2010 reduced the workforce by approximately 25% to focus resources on promising programs and reduce costs.
  • 7The company highlighted its extensive intellectual property portfolio and numerous strategic alliances with leading pharmaceutical and biotechnology companies.

Frequently Asked Questions

Alnylam's core strategy, termed 'Alnylam 5x15,' focuses on developing innovative RNAi therapeutics for genetically defined diseases. The goal is to advance five such programs into advanced clinical development by the end of 2015, with each program expected to target a genetically defined disease, address a significant unmet medical need, leverage Alnylam's delivery platform, allow for early biomarker monitoring, and have clear clinical endpoints for regulatory approval.

As of the February 2011 filing, Alnylam's most advanced core development programs were ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. They also had partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for RSV infection, ALN-VSP for liver cancers, and ALN-HTT for Huntington's disease.

Alnylam's revenue is primarily generated through strategic alliances and collaborations with pharmaceutical and biotechnology companies. These collaborations provide upfront payments, research funding, milestone payments, and potential royalties. For the year ended December 31, 2010, net revenues from these research collaborators totaled $100.0 million.

Alnylam acknowledges that its RNAi therapeutic approach is unproven and faces significant risks. These include challenges in demonstrating the safety and efficacy of siRNAs as drugs, potential off-target effects, activation of the interferon response, and difficulties in achieving adequate stability and cellular uptake of siRNAs. The company also faces substantial competition from other RNAi developers and established drug classes like antisense technology.